Mar 04, 2021 / 05:10PM GMT
Philip M. Nadeau - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Good afternoon, and welcome once again to Cowen and Company's 41st Annual Healthcare Conference. I'm Phil Nadeau, biotech analyst here at Cowen. It's my pleasure to introduce -- to moderate a fireside chat with Gilead Sciences. Happy to have with us today, Johanna Mercier, the Chief Commercial Officer; as well as Andy Dickinson, Chief Financial Officer.
First, maybe I'll turn it over to you guys. Could you just give a brief state of the company overview, biggest strengths, biggest challenges? And what needs to happen to continue to grow Gilead and create shareholder value over the next 12 to 24 months?
Andrew D. Dickinson - Gilead Sciences, Inc. - Executive VP & CFO
Sure. Hi, Phil. I'll start, and Johanna can jump in as well. Thanks for having us again at the conference. We appreciate it.
Look, I think it's -- we're really excited. 2021 is going to be an important year for Gilead. There's a real, palpable sense of excitement across the company
Gilead Sciences Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 04, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers